What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call
Recursion Pharmaceuticals (RXRX) reported Q3 updates, including 55% and 50% median reductions in upper and lower GI polyp burdens, respectively. REC-1245 showed partial responses in advanced solid tumors. Sanofi exercised an option, triggering a $10M payment. RXRX raised $200M in financing, extending cash runway into 2029. The company expects to start a registrational study in 2H 2027.
How this was made

The 30-second read
Why it matters
For RXRX, the combination of (1) clinical readouts and dose selection for REC-1245, (2) FDA discussion and planned registrational-study start timing, and (3) quantified cash and expense guidance into 2029 creates a multi-pronged catalyst set that can shift near-term positioning.
Market read
Traders can reassess RXRX’s pipeline risk and financing durability based on disclosed REC-1245 dose/tolerability details, FDA study-planning timeline, and the $200M follow-on plus 2026-2027 cash expense guidance.
What to watch
The FDA registrational-study timeline is contingent on regulatory alignment, and the most decision-critical endpoints are still slated for 2027, leaving near-term valuation sensitive to interim updates and partner execution.
Background
The piece summarizes Recursion Pharmaceuticals’ Q3 earnings call, covering GI polyp burden data, REC-1245 Phase I updates, partnership milestones, and financing/cash runway guidance.
Ticker impact
Recursion reported Q3 call updates including REC-1245 Phase I response rates, FDA discussion for a registrational GI study, and a $200M oversubscribed follow-on offering.
Likely upward bias as investors price in improved pipeline signals and extended runway, tempered by dose-limiting toxicity at higher REC-1245 dose.
The article discloses multiple decision-relevant items: REC-1245 expansion dose selection with no DLT at 45 mg, higher-dose DLTs, FDA study design discussions, and quantified financing and expense guidance into 2029.
Market effects
Reinforces investor focus on AI-enabled biotech platforms translating into early clinical signals and partner-funded development.
Primarily US biotech sentiment, with potential spillover to healthcare growth/biotech risk appetite.
Partnership milestones with Sanofi and Roche Genentech highlight continued global pharma interest in platform-driven discovery.
Counterpoint
Early Phase I response and disease control can be noisy; the higher-dose cohort showed DLTs, so efficacy versus tolerability may not translate cleanly into registrational success.
Key entities
- companyRecursion Pharmaceuticals
NASDAQ-listed biotech whose Q3 call covered GI program updates, REC-1245 Phase I results, partnership milestones, and follow-on financing/cash runway.
- partnerSanofi
Exercised an option on a potential first-in-class oral small-molecule candidate; triggered a $10M payment and future milestones/royalties.
- partnerRoche Genentech
Optioned a neuroscience target from Recursion’s biology maps; discovery underway.
- regulatorFDA
Discussed registrational-study design with Recursion for a GI program, with targeted start in 2H 2027 subject to alignment.



